Navigation Links
La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial

of 2006 and completion of enrollment is targeted for around the end of 2007.

About Riquent

Riquent is being developed to specifically treat lupus renal disease by preventing or delaying renal flares, a leading cause of sickness and death in lupus patients. Riquent has been well tolerated in all 13 clinical trials, with no serious Riquent-related side effects identified to date. Riquent's only known biological activity is the reduction of circulating levels of anti-dsDNA antibodies. Increases in these antibodies are associated with an increased risk of renal flare. Although clinical benefit has not yet been proven, Riquent treatment has significantly reduced these antibody levels in all clinical trials where they were measured.

About Lupus

Lupus is a chronic, potentially life-threatening autoimmune disease. About 90% of lupus patients are female, and many are diagnosed with the disease during their childbearing years. Approximately 50% of lupus patients have renal disease, which can lead to irreversible renal damage, renal failure and the need for dialysis, and is a leading cause of death in lupus patients. Latinos, African Americans and Asians face an increased risk of serious renal disease associated with lupus. The current standard of care for lupus renal disease often involves treatment with high doses of corticosteroids and immunosuppressive drugs that can cause severe side effects including diabetes, hypertension and sterility, and may leave patients vulnerable to opportunistic infections. To date, no lupus specific drug has been approved in the U.S.

La Jolla Pharmaceutical Company is dedicated to improving and preserving human life by developing innovative pharmaceutical products. The Company's leading product in development is Riquent. The Company has also developed small molecules to treat various other autoimmune and inflammatory conditions. The Company's common stock is traded on The NASDAQ Global Market under the symbol
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:7/30/2015)... OAKS, Calif., July 30, 2015  Amgen (NASDAQ: ... the second quarter of 2015. Key results include: ... the second quarter of 2014 to $5,370 million, ... by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable changes ...
(Date:7/30/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... the notice it received on May 21, 2015 from ... Company was below certain of the Exchange,s continued listing ... of the NYSE MKT Company Guide, due to the ...
(Date:7/30/2015)... , July 30, 2015  Growth of the U.S. ... they bring former prescription users to the OTC market. ... forecasts robust Rx-to-OTC switch activity over the next ... along with many new brands entering the market into ... the next five years (even those with low to ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... Company (NYSE:  KVa/KVb) announced today that it has entered into ... II, L.L.C. for a $20 million loan secured by assets ... loan for working capital and general operating purposes.   ... L.L.C. and U.S. Healthcare II, L.L.C., has entered into a ...
... leader in centralized expert evaluation of CNS disorders, announced ... has approved the first New Drug Application (NDA) for ... MedAvante centralized raters. Johnson and Johnson Pharmaceutical ... for the drug paliperidone palmitate, now known as Invega ...
Cached Medicine Technology:K-V Pharmaceutical Company Secures $20 Million Loan 2K-V Pharmaceutical Company Secures $20 Million Loan 3K-V Pharmaceutical Company Secures $20 Million Loan 4K-V Pharmaceutical Company Secures $20 Million Loan 5K-V Pharmaceutical Company Secures $20 Million Loan 6K-V Pharmaceutical Company Secures $20 Million Loan 7K-V Pharmaceutical Company Secures $20 Million Loan 8FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters 2FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters 3
(Date:7/31/2015)... ... ... Down is a reputable source of authentic tickets for the 2015 iHeart Radio Music ... genre of music will have an act they are excited to see at this two-day ... artists will perform: Sam Smith, Coldplay, Kenny Chesney, The Who, Jason Derulo, Demi Lovato, ...
(Date:7/31/2015)... ... ... The Honor Society of Nursing, Sigma Theta Tau International (STTI) convened a ... July 2015 in San Juan, Puerto Rico. Key nurse leaders from Central and Latin ... Nursing and Allied Health Personnel Development, Unit of Human Resources for Health, Department of ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Ticket Down ... is currently going on in Chicago at Grant Park. The festival will end ... of North America to Chicago for the annual Lollapalooza. This unique and unbelievably ...
(Date:7/31/2015)... ... 2015 , ... Recently touted by Becker’s Healthcare as one ... , Jvion continues to disrupt the predictive analytic and big data market using ... population level illness to drive prevention and better health outcomes. Most recently, Jvion ...
(Date:7/31/2015)... ... , ... The 2nd annual Ride to Fight On will start and end ... The Ride to Fight On is a cycling fundraiser that benefits the West Cancer ... and The University of Tennessee Health Science Center. A health and wellness festival featuring ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3
... Scientists working at the Medical Research Council have identified ... pre-cancerous cells in the esophagus, a condition called Barrett,s ... these cells before they develop into esophageal cancer. These ... have important implications for patients and may help to ...
... News) -- Soccer players need to use the correct ... or redirect the ball -- to prevent possible brain injury, ... link between the sport and brain damage, Dr. Alejandro Spiotta ... are moving at high speeds when they come into contact ...
... -- A study about how wearing contact lenses affects ... Loyola University Chicago Stritch School of Medicine,s annual St. ... study is Marie Brenner, a fourth-year student at Stritch ... effects of contact lens wear on retinal nerve fiber ...
... an accepted way to simplify a complex array of symptoms ... an independent disease in itself. However, the truth is not ... at work explaining the symptoms. This is also one of ... not bring the hoped result," says Kari Tikkinen, MD, PhD, ...
... The University of Kentucky will be the first site ... the entire country participating in the first stages of a ... human adult stem cell product, on patients with acute ischemic ... stroke protocol B01-02, was recently approved by UK,s institutional review ...
... By Alan Mozes HealthDay Reporter , ... smartphone may not actually be that smart, British researchers ... study that finds an association between the increasingly popular ... levels. The reason: a relentless need to immediately ...
Cached Medicine News:Health News:Researchers use sugar to halt esophageal cancer in its tracks 2Health News:Heading Soccer Balls Could Injure Brain 2Health News:The concept of 'overactive bladder' serves better commercial rather than patient interests 2Health News:Your Smartphone May Be Stressing You Out 2Health News:Your Smartphone May Be Stressing You Out 3
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
... for continuous, random access operation, the Elecsys ... to large volume laboratories that want to ... the simplicity, flexibility and Stat capabilities of ... be adapted to the changing needs of ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
... The SkanWasher 400 ... 96-well microplate washer with ... pumps. The individual pressure ... a very gentle wash ...
Medicine Products: